Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
Ozgecan DulgarBala Başak ÖvenMuhammet Mustafa AtcıRukiye ArıkanSeval AyMurat AyhanOğuzhan SelviDeniz Tataroğlu ÖzyükselerErtuğrul BayramErkan ÖzcanAyse Irem YasinMahmut GümüşPublished in: Expert review of anticancer therapy (2022)
This multicenter-study suggested that only the poor-response group to NAC achieved benefit from adjuvant capecitabine. Postmenopausal status and residual tumor-size were related to poor prognosis.
Keyphrases
- poor prognosis
- neoadjuvant chemotherapy
- locally advanced
- rectal cancer
- long non coding rna
- early stage
- phase ii study
- squamous cell carcinoma
- radiation therapy
- sentinel lymph node
- transcription factor
- lymph node
- metastatic breast cancer
- metastatic colorectal cancer
- phase iii
- bone mineral density
- clinical trial
- randomized controlled trial
- open label